TORONTO, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, the Maxim Group Mental Health Conference and the Cantor Virtual Global Health Conference in September 2021.
H.C. Wainwright 23rd Annual Global Investment Conference: September 13th-15th 2021
Field Trip’s Co-founder and CEO, Joseph Del Moral, and Field Trip’s Chief Scientific Officer, Dr. Nathan Bryson, will participate in a Fireside Chat at the H.C. Wainwright 23rd Annual Global Investment Conference. The Fireside Chat will be pre-recorded and will be accessible to those registered for the conference from Monday, September 13th at 7:00am Eastern Time through Wednesday, September 15th 2021.
Additionally, the Field Trip management team will participate in virtual one-on-one meetings for the duration of the conference. To schedule a meeting or to request further information on the conference, please contact your H.C. Wainwright representative or KCSA Strategic Communications at fieldtripIR@kcsa.com.
Oppenheimer Fall Healthcare Life Sciences and MedTech Summit: September 21st-23rd 2021
Field Trip’s Co-founder and CEO, Joseph Del Moral, and Field Trip’s Chief Scientific Officer, Dr. Nathan Bryson, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit at 2:55pm Eastern Time on Tuesday, September 21st 2021.
The presentation will be webcast and available through this link: https://wsw.com/webcast/oppenheimer16/ftrp/2808276.
A recording of the presentation will be accessible on the Field Trip website for 90 days in the Investor Relations section under Events and Presentations.
To request a virtual one-on-one meeting with the Field Trip management team, or for further information on the conference, please contact your Oppenheimer representative or KCSA Strategic Communications at fieldtripIR@kcsa.com.
Maxim Group Advances in Mental Health Conference: September 22nd 2021
Field Trip’s Co-founder and CEO, Joseph Del Moral, and Field Trip’s Chief Scientific Officer, Dr. Nathan Bryson, will participate in Maxim Group’s Advances in Mental Health Conference, which will be held virtually on Wednesday, September 22nd 2021. As part of the “Disruptors in the Mental Health Space” virtual panel series, Field Trip will participate in the Next-Gen Novel Chemical Entities and the Clinics and Commercialization panels.
For more information about the conference, or to request a one-on-one meeting with Field Trip management, please contact your Maxim Group representative or KCSA Strategic Communications at fieldtripIR@kcsa.com.
Cantor Virtual Global Health Conference: September 27th-30th 2021
Field Trip’s Co-founder and Executive Chairman, Ronan Levy, and Field Trip’s Chief Scientific Officer, Dr. Nathan Bryson, will present at the Cantor Virtual Global Health Conference at 9:20am Eastern Time on Wednesday, September 29th 2021.
The presentation will be webcast and available through this link: https://wsw.com/webcast/cantor12/ftrp/2105880.
A recording of the presentation will be accessible on the Field Trip website for 180 days in the Investor Relations section under Events and Presentations.
The Field Trip management team will also be participating in one-on-one meetings during the conference. To schedule a meeting, or to request more information, please contact your Cantor Fitzgerald representative or KCSA Strategic Communications at fieldtripIR@kcsa.com.
About Field Trip Health Ltd.
Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.
Follow us on Twitter and Instagram: @fieldtriphealth.
To receive company updates about Field Trip and to be added to the email distribution list please sign up here.
Cautionary Note Regarding Forward-Looking Information
This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including interest in the training program, interest in the KAP Co-Op Program, uptake of the KAP Co-Op Program by therapists and patients, the timing and results of its research and development programs, approval of phase 1 human trials, if any, the risk that future clinical studies may not proceed as expected or may produce unfavorable results, the opening of additional clinics, the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management's ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.
Nick Opich / McKenna Miller
KCSA Strategic Communications
212-896-1206 / 347-487-6197
Kathleen Heaney / Tim Regan
KCSA Strategic Communications
SOURCE Field Trip Health Ltd.